Spexin-based galanin receptor type 2 agonist for comorbid mood disorders and abnormal body weight

Seongsik Yun, Arfaxad Reyes-Alcaraz, Yoo Na Lee, Hyo Jeong Yong, Jeewon Choi, Byung-Joo Ham, Jong Woo Sohn, Dong-Hun Kim, Gi Hoon Son, Hyun Kim, Soon Gu Kwon, Dong Sik Kim, Bong Chul Kim, Jong-Ik Hwang, Jae Young Seong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite the established comorbidity between mood disorders and abnormal eating behaviors, the underlying molecular mechanism and therapeutics remain to be resolved. Here, we show that a spexin-based galanin receptor type 2 agonist (SG2A) simultaneously normalized mood behaviors and body weight in corticosterone pellet-implanted (CORTI) mice, which are underweight and exhibit signs of anhedonia, increased anxiety, and depression. Administration of SG2A into the lateral ventricle produced antidepressive and anxiolytic effects in CORTI mice. Additionally, SG2A led to a recovery of body weight in CORTI mice while it induced significant weight loss in normal mice. In Pavlovian fear-conditioned mice, SG2A decreased contextual and auditory fear memory consolidation but accelerated the extinction of acquired fear memory without altering innate fear and recognition memory. The main action sites of SG2A in the brain may include serotonergic neurons in the dorsal raphe nucleus for mood control, and proopiomelanocortin/corticotropin-releasing hormone neurons in the hypothalamus for appetite and body weight control. Furthermore, intranasal administration of SG2A exerted the same anxiolytic and antidepressant-like effects and decreased food intake and body weight in a dose-dependent manner. Altogether, these results indicate that SG2A holds promise as a clinical treatment for patients with comorbid mood disorders and abnormal appetite/body weight.

Original languageEnglish
Article number391
JournalFrontiers in Neuroscience
Volume13
Issue numberAPR
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Receptor, Galanin, Type 2
Mood Disorders
Body Weight
Fear
Corticosterone
Anti-Anxiety Agents
Appetite
Anhedonia
Serotonergic Neurons
Intranasal Administration
Pro-Opiomelanocortin
Thinness
Lateral Ventricles
Corticotropin-Releasing Hormone
Feeding Behavior
Antidepressive Agents
Hypothalamus
Comorbidity
Weight Loss
Anxiety

Keywords

  • Appetite
  • Body weight
  • Depression
  • Galanin receptor 2 agonist
  • Intranasal administration
  • Post-traumatic stress disorder

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Spexin-based galanin receptor type 2 agonist for comorbid mood disorders and abnormal body weight. / Yun, Seongsik; Reyes-Alcaraz, Arfaxad; Lee, Yoo Na; Yong, Hyo Jeong; Choi, Jeewon; Ham, Byung-Joo; Sohn, Jong Woo; Kim, Dong-Hun; Son, Gi Hoon; Kim, Hyun; Kwon, Soon Gu; Kim, Dong Sik; Kim, Bong Chul; Hwang, Jong-Ik; Seong, Jae Young.

In: Frontiers in Neuroscience, Vol. 13, No. APR, 391, 01.01.2019.

Research output: Contribution to journalArticle

Yun, Seongsik ; Reyes-Alcaraz, Arfaxad ; Lee, Yoo Na ; Yong, Hyo Jeong ; Choi, Jeewon ; Ham, Byung-Joo ; Sohn, Jong Woo ; Kim, Dong-Hun ; Son, Gi Hoon ; Kim, Hyun ; Kwon, Soon Gu ; Kim, Dong Sik ; Kim, Bong Chul ; Hwang, Jong-Ik ; Seong, Jae Young. / Spexin-based galanin receptor type 2 agonist for comorbid mood disorders and abnormal body weight. In: Frontiers in Neuroscience. 2019 ; Vol. 13, No. APR.
@article{1d7d82016a3c443c8780c5dc20de83b5,
title = "Spexin-based galanin receptor type 2 agonist for comorbid mood disorders and abnormal body weight",
abstract = "Despite the established comorbidity between mood disorders and abnormal eating behaviors, the underlying molecular mechanism and therapeutics remain to be resolved. Here, we show that a spexin-based galanin receptor type 2 agonist (SG2A) simultaneously normalized mood behaviors and body weight in corticosterone pellet-implanted (CORTI) mice, which are underweight and exhibit signs of anhedonia, increased anxiety, and depression. Administration of SG2A into the lateral ventricle produced antidepressive and anxiolytic effects in CORTI mice. Additionally, SG2A led to a recovery of body weight in CORTI mice while it induced significant weight loss in normal mice. In Pavlovian fear-conditioned mice, SG2A decreased contextual and auditory fear memory consolidation but accelerated the extinction of acquired fear memory without altering innate fear and recognition memory. The main action sites of SG2A in the brain may include serotonergic neurons in the dorsal raphe nucleus for mood control, and proopiomelanocortin/corticotropin-releasing hormone neurons in the hypothalamus for appetite and body weight control. Furthermore, intranasal administration of SG2A exerted the same anxiolytic and antidepressant-like effects and decreased food intake and body weight in a dose-dependent manner. Altogether, these results indicate that SG2A holds promise as a clinical treatment for patients with comorbid mood disorders and abnormal appetite/body weight.",
keywords = "Appetite, Body weight, Depression, Galanin receptor 2 agonist, Intranasal administration, Post-traumatic stress disorder",
author = "Seongsik Yun and Arfaxad Reyes-Alcaraz and Lee, {Yoo Na} and Yong, {Hyo Jeong} and Jeewon Choi and Byung-Joo Ham and Sohn, {Jong Woo} and Dong-Hun Kim and Son, {Gi Hoon} and Hyun Kim and Kwon, {Soon Gu} and Kim, {Dong Sik} and Kim, {Bong Chul} and Jong-Ik Hwang and Seong, {Jae Young}",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fnins.2019.00391",
language = "English",
volume = "13",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "APR",

}

TY - JOUR

T1 - Spexin-based galanin receptor type 2 agonist for comorbid mood disorders and abnormal body weight

AU - Yun, Seongsik

AU - Reyes-Alcaraz, Arfaxad

AU - Lee, Yoo Na

AU - Yong, Hyo Jeong

AU - Choi, Jeewon

AU - Ham, Byung-Joo

AU - Sohn, Jong Woo

AU - Kim, Dong-Hun

AU - Son, Gi Hoon

AU - Kim, Hyun

AU - Kwon, Soon Gu

AU - Kim, Dong Sik

AU - Kim, Bong Chul

AU - Hwang, Jong-Ik

AU - Seong, Jae Young

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite the established comorbidity between mood disorders and abnormal eating behaviors, the underlying molecular mechanism and therapeutics remain to be resolved. Here, we show that a spexin-based galanin receptor type 2 agonist (SG2A) simultaneously normalized mood behaviors and body weight in corticosterone pellet-implanted (CORTI) mice, which are underweight and exhibit signs of anhedonia, increased anxiety, and depression. Administration of SG2A into the lateral ventricle produced antidepressive and anxiolytic effects in CORTI mice. Additionally, SG2A led to a recovery of body weight in CORTI mice while it induced significant weight loss in normal mice. In Pavlovian fear-conditioned mice, SG2A decreased contextual and auditory fear memory consolidation but accelerated the extinction of acquired fear memory without altering innate fear and recognition memory. The main action sites of SG2A in the brain may include serotonergic neurons in the dorsal raphe nucleus for mood control, and proopiomelanocortin/corticotropin-releasing hormone neurons in the hypothalamus for appetite and body weight control. Furthermore, intranasal administration of SG2A exerted the same anxiolytic and antidepressant-like effects and decreased food intake and body weight in a dose-dependent manner. Altogether, these results indicate that SG2A holds promise as a clinical treatment for patients with comorbid mood disorders and abnormal appetite/body weight.

AB - Despite the established comorbidity between mood disorders and abnormal eating behaviors, the underlying molecular mechanism and therapeutics remain to be resolved. Here, we show that a spexin-based galanin receptor type 2 agonist (SG2A) simultaneously normalized mood behaviors and body weight in corticosterone pellet-implanted (CORTI) mice, which are underweight and exhibit signs of anhedonia, increased anxiety, and depression. Administration of SG2A into the lateral ventricle produced antidepressive and anxiolytic effects in CORTI mice. Additionally, SG2A led to a recovery of body weight in CORTI mice while it induced significant weight loss in normal mice. In Pavlovian fear-conditioned mice, SG2A decreased contextual and auditory fear memory consolidation but accelerated the extinction of acquired fear memory without altering innate fear and recognition memory. The main action sites of SG2A in the brain may include serotonergic neurons in the dorsal raphe nucleus for mood control, and proopiomelanocortin/corticotropin-releasing hormone neurons in the hypothalamus for appetite and body weight control. Furthermore, intranasal administration of SG2A exerted the same anxiolytic and antidepressant-like effects and decreased food intake and body weight in a dose-dependent manner. Altogether, these results indicate that SG2A holds promise as a clinical treatment for patients with comorbid mood disorders and abnormal appetite/body weight.

KW - Appetite

KW - Body weight

KW - Depression

KW - Galanin receptor 2 agonist

KW - Intranasal administration

KW - Post-traumatic stress disorder

UR - http://www.scopus.com/inward/record.url?scp=85068361240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068361240&partnerID=8YFLogxK

U2 - 10.3389/fnins.2019.00391

DO - 10.3389/fnins.2019.00391

M3 - Article

AN - SCOPUS:85068361240

VL - 13

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - APR

M1 - 391

ER -